Platelet bioenergetic screen in sickle cell patients reveals mitochondrial complex V inhibition, which contributes to platelet activation

Blood

Volumn 123, Issue 18, 2014, Pages 2864-2872

  Cardenes, Nayra ^a   Corey, Catherine ^a   Geary, Lisa ^a   Jain, Shilpa ^a   Zharikov, Sergey ^a   Barge, Suchitra ^a   Novelli, Enrico M ^a,b   Shiva, Sruti ^a,b  

^a CHILDREN S HOSPITAL OF PITTSBURGH   (United States)

^b UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALLOPURINOL; HEMOGLOBIN; INDOMETACIN; MITOCHONDRIAL COMPLEX V; OLIGOMYCIN; OXIDIZING AGENT; OXIDOREDUCTASE; PROSTAGLANDIN SYNTHASE INHIBITOR; REACTIVE OXYGEN METABOLITE; UNCLASSIFIED DRUG; XANTHINE OXIDASE INHIBITOR;

ANALYTIC METHOD; ARTICLE; BIOENERGETIC DYSFUNCTION; BIOENERGY; BREATHING RATE; CLINICAL ARTICLE; CONTROLLED STUDY; DISORDERS OF MITOCHONDRIAL FUNCTIONS; ENZYME INHIBITION; EXTRACELLULAR FLUX ANALYSIS; HEMOLYSIS; HIGH THROUGHPUT SCREENING; HUMAN; HUMAN CELL; HYPERPOLARIZATION; MITOCHONDRIAL RESPIRATION; MITOCHONDRION; OXYGEN CONSUMPTION; OXYGEN CONSUMPTION RATE; PRIORITY JOURNAL; RESPIRATORY CHAIN; SICKLE CELL ANEMIA; THROMBOCYTE ACTIVATION; THROMBOCYTE AGGREGATION; THROMBOCYTE COUNT;

ADENOSINE TRIPHOSPHATASES; ADULT; ANEMIA, SICKLE CELL; BLOOD PLATELETS; CARRIER PROTEINS; CASE-CONTROL STUDIES; FEMALE; HEMOLYSIS; HUMANS; MALE; MEMBRANE PROTEINS; MIDDLE AGED; MITOCHONDRIA; OXYGEN CONSUMPTION; PLATELET ACTIVATION; PLATELET AGGREGATION; REACTIVE OXYGEN SPECIES; REPRODUCIBILITY OF RESULTS; YOUNG ADULT;

EID: 84902842760     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2013-09-529420     Document Type: Article

References (48)

1. Schapira AH, Gu M, Taanman JW, et al. Mitochondria in the etiology and pathogenesis of Parkinson's disease. Ann Neurol. 1998;44(3 Suppl 1):S89-S98. (Pubitemid 28423834)
2. Sj̈ovall F, Morota S, Hansson MJ, Friberg H, Gnaiger E, Elmér E. Temporal increase of platelet mitochondrial respiration is negatively associated with clinical outcome in patients with sepsis. Crit Care. 2010;14(6):R214.
3. Blandini F, Nappi G, Greenamyre JT. Quantitative study of mitochondrial complex I in platelets of parkinsonian patients. Mov Disord. 1998;13(1):11-15. (Pubitemid 28029845)
4. Shults CW, Haas RH, Passov D, Beal MF. Coenzyme Q10 levels correlate with the activities of complexes I and II/III in mitochondria from parkinsonian and nonparkinsonian subjects. Ann Neurol. 1997;42(2):261-264. (Pubitemid 27340475)
5. Lorente L, Iceta R, Martín MM, et al. Survival and mitochondrial function in septic patients according to mitochondrial DNA haplogroup. Crit Care. 2012;16(1):R10.
6. Avila C, Huang RJ, Stevens MV, et al. Platelet mitochondrial dysfunction is evident in type 2 diabetes in association with modifications of mitochondrial anti-oxidant stress proteins. Exp Clin Endocrinol Diabetes. 2012;120(4):248-251.
7. Guo X, Wu J, Du J, Ran J, Xu J. Platelets of type 2 diabetic patients are characterized by high ATP content and low mitochondrial membrane potential. Platelets. 2009;20(8):588-593.
8. Holmsen H, Day HJ, Pimentel M. Adenine nucleotide metabolism of blood platelets. V. Subcellular localization of some related enzymes. Biochim Biophys Acta. 1969;186(2):244-253.
9. Salganicoff L, Fukami MH. Energy metabolism of blood platelets. I. Isolation and properties of platelet mitochondria. Arch Biochem Biophys. 1972;153(2):726-735.
10. Jobe SM, Wilson KM, Leo L, et al. Critical role for the mitochondrial permeability transition pore and cyclophilin D in platelet activation and thrombosis. Blood. 2008;111(3):1257-1265. (Pubitemid 351213408)
11. Matarrese P, Straface E, Palumbo G, et al. Mitochondria regulate platelet metamorphosis induced by opsonized zymosan A - activation and long-term commitment to cell death. FEBS J. 2009;276(3):845-856.
12. Yamagishi SI, Edelstein D, Du XL, Brownlee M. Hyperglycemia potentiates collagen-induced platelet activation through mitochondrial superoxide overproduction. Diabetes. 2001;50(6):1491-1494. (Pubitemid 32500184)
13. Blann AD, Marwah S, Serjeant G, et al. Platelet activation and endothelial cell dysfunction in sickle cell disease is unrelated to reduced antioxidant capacity. Blood Coagul Fibrinolysis. 2003;14(3):255-259. (Pubitemid 36589147)
14. Tomer A, Harker LA, Kasey S, Eckman JR. Thrombogenesis in sickle cell disease. J Lab Clin Med. 2001;137(6):398-407. (Pubitemid 32473618)
15. Villagra J, Shiva S, Hunter LA, Machado RF, Gladwin MT, Kato GJ. Platelet activation in patients with sickle disease, hemolysis-associated pulmonary hypertension, and nitric oxide scavenging by cell-free hemoglobin. Blood. 2007;110(6):2166-2172. (Pubitemid 47443936)
16. Wun T, Paglieroni T, Rangaswami A, et al. Platelet activation in patients with sickle cell disease. Br J Haematol. 1998;100(4):741-749. (Pubitemid 28126109)
17. Antonucci R, Walker R, Herion J, Orringer E. Enhancement of sickle erythrocyte adherence to endothelium by autologous platelets. Am J Hematol. 1990;34(1):44-48. (Pubitemid 20139486)
18. Brittain HA, Eckman JR, Swerlick RA, Howard RJ, Wick TM. Thrombospondin from activated platelets promotes sickle erythrocyte adherence to human microvascular endothelium under physiologic flow: a potential role for platelet activation in sickle cell vaso-occlusion. Blood. 1993;81(8):2137-2143. (Pubitemid 23106730)
19. Ross R, Glomset J, Kariya B, Harker L. A platelet-dependent serum factor that stimulates the proliferation of arterial smooth muscle cells in vitro. Proc Natl Acad Sci USA. 1974;71(4):1207-1210.
20. Yu E, Mercer J, Bennett M. Mitochondria in vascular disease. Cardiovasc Res. 2012;95(2):173-182.
21. Dromparis P, Sutendra G, Michelakis ED. The role of mitochondria in pulmonary vascular remodeling. J Mol Med (Berl). 2010;88(10):1003-1010.
22. Chacko BK, Kramer PA, Ravi S, et al. Methods for defining distinct bioenergetic profiles in platelets, lymphocytes, monocytes, and neutrophils, and the oxidative burst from human blood. Lab Invest. 2013;93(6):690-700.
23. Fink BD, Herlein JA, O'Malley Y, Sivitz WI. Endothelial cell and platelet bioenergetics: effect of glucose and nutrient composition. PLoS ONE. 2012;7(6):e39430.
24. Walkowiak B, Kesy A, Michalec L. Microplate reader - a convenient tool in studies of blood coagulation. Thromb Res. 1997;87(1):95-103. (Pubitemid 27333266)
25. Mo L, Wang Y, Geary L, et al. Nitrite activates AMP kinase to stimulate mitochondrial biogenesis independent of soluble guanylate cyclase. Free Radic Biol Med. 2012;53(7):1440-1450.
26. Shiva S, Rassaf T, Patel RP, Gladwin MT. The detection of the nitrite reductase and NO-generating properties of haemoglobin by mitochondrial inhibition. Cardiovasc Res. 2011; 89(3):566-573.
27. Minneci PC, Deans KJ, Shiva S, et al. Nitrite reductase activity of hemoglobin as a systemic nitric oxide generator mechanism to detoxify plasma hemoglobin produced during hemolysis. Am J Physiol Heart Circ Physiol. 2008;295(2):H743-H754.
28. Aslan M, Ryan TM, Adler B, et al. Oxygen radical inhibition of nitric oxide-dependent vascular function in sickle cell disease. Proc Natl Acad Sci USA. 2001;98(26):15215-15220. (Pubitemid 34013994)
29. Kato GJ, Gladwin MT, Steinberg MH. Deconstructing sickle cell disease: reappraisal of the role of hemolysis in the development of clinical subphenotypes. Blood Rev. 2007;21(1):37-47. (Pubitemid 46110926)
30. Wun T, Paglieroni T, Tablin F, Welborn J, Nelson K, Cheung A. Platelet activation and platelet-erythrocyte aggregates in patients with sickle cell anemia. J Lab Clin Med. 1997;129(5):507-516. (Pubitemid 27285047)
31. Ataga KI, Moore CG, Jones S, et al. Pulmonary hypertension in patients with sickle cell disease: a longitudinal study. Br J Haematol. 2006;134(1):109-115. (Pubitemid 43830036)
32. Gladwin MT, Sachdev V, Jison ML, et al. Pulmonary hypertension as a risk factor for death in patients with sickle cell disease. N Engl J Med. 2004;350(9):886-895. (Pubitemid 38252536)
33. Wun T, Soulieres D, Frelinger AL, et al. A double-blind, randomized, multicenter phase 2 study of prasugrel versus placebo in adult patients with sickle cell disease. J Hematol Oncol. 2013;6:17.
34. Snow BJ, Rolfe FL, Lockhart MM, et al. A double-blind, placebo-controlled study to assess the mitochondria-targeted antioxidant MitoQ as a disease-modifying therapy in Parkinson's disease. Mov Disord. 2010;25(11):1670-1674.
35. Bosetti F, Brizzi F, Barogi S, et al. Cytochrome c oxidase and mitochondrial F1F0-ATPase (ATP synthase) activities in platelets and brain from patients with Alzheimer's disease. Neurobiol Aging. 2002;23(3):371-376. (Pubitemid 34312019)
36. Dromparis P, Paulin R, Sutendra G, Qi AC, Bonnet S, Michelakis ED. Uncoupling protein 2 deficiency mimics the effects of hypoxia and endoplasmic reticulum stress on mitochondria and triggers pseudohypoxic pulmonary vascular remodeling and pulmonary hypertension. Circ Res. 2013;113(2):126-136.
37. Chandel NS, McClintock DS, Feliciano CE, et al. Reactive oxygen species generated at mitochondrial complex III stabilize hypoxia-inducible factor-1alpha during hypoxia: a mechanism of O2 sensing. J Biol Chem. 2000; 275(33):25130-25138.
38. Kaul DK, Fabry ME, Suzuka SM, Zhang X. Antisickling fetal hemoglobin reduces hypoxia-inducible factor-1α expression in normoxic sickle mice: microvascular implications. Am J Physiol Heart Circ Physiol. 2013;304(1):H42-H50.
39. Patel N, Gonsalves CS, Malik P, Kalra VK. Placenta growth factor augments endothelin-1 and endothelin-B receptor expression via hypoxia-inducible factor-1 alpha. Blood. 2008;112(3):856-865.
40. Bonnet S, Michelakis ED, Porter CJ, et al. An abnormal mitochondrial-hypoxia inducible factor-1alpha-Kv channel pathway disrupts oxygen sensing and triggers pulmonary arterial hypertension in fawn hooded rats: similarities to human pulmonary arterial hypertension. Circulation. 2006;113(22):2630-2641. (Pubitemid 43948012)
41. Kane LA, Van Eyk JE. Post-translational modifications of ATP synthase in the heart: biology and function. J Bioenerg Biomembr. 2009;41(2):145-150.
42. Wang SB, Murray CI, Chung HS, Van Eyk JE. Redox regulation of mitochondrial ATP synthase. Trends Cardiovasc Med. 2013;23(1):14-18.
43. Reiter CD, Wang X, Tanus-Santos JE, et al. Cell-free hemoglobin limits nitric oxide bioavailability in sickle-cell disease. Nat Med. 2002;8(12):1383-1389. (Pubitemid 36019423)
44. Aslan M, Thornley-Brown D, Freeman BA. Reactive species in sickle cell disease. Ann N Y Acad Sci. 2000;899:375-391. (Pubitemid 30352801)
45. Hebbel RP. Auto-oxidation and a membrane-associated 'Fenton reagent': a possible explanation for development of membrane lesions in sickle erythrocytes. Clin Haematol. 1985;14(1):129-140.
46. Dayal S, Wilson KM, Motto DG, Miller FJ Jr, Chauhan AK, Lentz SR. Hydrogen peroxide promotes aging-related platelet hyperactivation and thrombosis. Circulation. 2013;127(12):1308-1316.
47. Pignatelli P, Pulcinelli FM, Lenti L, Gazzaniga PP, Violi F. Hydrogen peroxide is involved in collagen-induced platelet activation. Blood. 1998;91(2):484-490. (Pubitemid 28053370)
48. Choo HJ, Saafir TB, Mkumba L, Wagner MB, Jobe SM. Mitochondrial calcium and reactive oxygen species regulate agonist-initiated platelet phosphatidylserine exposure. Arterioscler Thromb Vasc Biol. 2012;32(12):2946- 2955.